Dementia

Remaining challenges in bringing fluid biomarkers into clinical practice

Bringing the pTau/Aβ42 biomarker into the clinic

Promise of microRNAs as Alzheimer’s disease markers

Targeting the pancreas to treat Alzheimer’s disease

Diabetes-associated cognitive dysfunction

Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI

New pivotal study using photobiomodulation in Alzheimer’s treatment

The regulatory role of nicotinic receptors in cognitive functioning

The importance of using systems biology based approaches in AD research

How effective are cholinergic agents beyond MCI?

Highlights from CTAD 2022

Prioritizing the mechanistic understanding of AD to improve treatments

Photobiomodulation: why target the brain and the gut?

Longitudinal clinical outcomes of tau-PET-positive individuals

Clinical implementations of AlzoSure Predict

Predicting tau-PET signal in early Alzheimer’s disease using speech biomarkers